health
Ulcerative Colitis Response Patterns Reveal a Vedolizumab Resistance Signal
A study in Nature Medicine grouped ulcerative colitis patients by how quickly their symptoms changed during treatment and linked vedolizumab nonresponse to SPP1-associated vascular inflammation. Retrospective cohorts also associated ACE inhibitor or ARB use with better outcomes for patients taking vedolizumab, a finding that needs prospective trial testing.